Use of PIWI-interacting RNA piR-hsa-211106

US12180476B2 · kind B2 · utility

Inventors

• Wenhua Xu · Jiaozuo City, CN
• Yongmei Liu · Gilbert, US
• Yanhan Dong · Shandong, CN
• Jinning Gao · Qingdao, CN
• Xiaodan Hao · Qingdao, CN
• Zibo Wang · Redmond, US
• Meng Li · Nanning, CN

Key dates

• Filing date: Feb 7, 2022
• Grant date: Dec 31, 2024
• Expiry date: Aug 4, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In the field of biomedical technology, a PIWI-interacting RNA piR-hsa-211106 is used to prepare a targeted therapeutic drug for inhibiting proliferation of lung adenocarcinoma cells. A mechanism is as follows: after the PIWI-interacting RNA piR-hsa-211106 is constructed into an agonist or a transformant, the agonist or the transformant inhibits a tricarboxylic acid cycle process by down-regulating an expression of a pyruvate carboxylase, inhibits an energy metabolism, promotes apoptosis of the lung adenocarcinoma cells, thus inhibits growth of the lung adenocarcinoma. The PIWI-interacting RNA piR-hsa-211106 directly acts on a target site and does not produce toxic and side effects and an off-target phenomenon. Large amounts of analysis and in-vivo and in-vitro experiments show that the PIWI-interacting RNA piR-hsa-211106 has high credibility and a remarkable treatment effect, and provides a new research direction for anti-tumor therapy of lung adenocarcinoma.